|
30 Mar 2007 |
Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin(R) in Preclinical Studies
|
|
29 Mar 2007 |
Protox Initiates Phase I Study of PRX302 for Benign Prostatic Hyperplasia
|
|
28 Mar 2007 |
CoGenesys, Inc. Expands Clinical Programs with Initiation of Phase 1-2a Trial of Neugranin in Cancer Patients
|
|
27 Mar 2007 |
Novartis to launch its own branded version of a leading multiple sclerosis therapy through agreement with Bayer Schering Pharma
|
|
27 Mar 2007 |
Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
|
|
27 Mar 2007 |
CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume in Coronary Arteries
|
|
27 Mar 2007 |
ACUITY One-Year Findings Meet All Primary Endpoints in Favor of Angiomax(R) (Bivalirudin) Alone Treatment Group
|
|
26 Mar 2007 |
Scios Announces Results From Exploratory Nesiritide Study Providing Important New Renal and Mortality Safety Data with a Neutral Effect on the Primary Endpoint
|
|
23 Mar 2007 |
Æterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
|
|
22 Mar 2007 |
BioGeneriX and Neose Announce Initiation of 2nd Phase I Clinical Trial of GlycoPEG-GCSF; Interim Results From 1st Phase I Trial Show Dose-Dependent Response
|
|
22 Mar 2007 |
BioLineRx In-Licenses Novel Peptide for the Treatment of Inflammatory Diseases
|
|
21 Mar 2007 |
Talecris Initiates Clinical Development Program Evaluating Plasmin for Dissolving Blood Clots and Restoring Blood Flow in Legs
|
|
21 Mar 2007 |
Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis
|
|
21 Mar 2007 |
Potentia Pharmaceuticals Announces Initiation of Phase I Clinical Trials to Evaluate its Lead Compound for Age-Related Macular Degeneration
|
|
16 Mar 2007 |
Affibody to publish data on therapeutic effects of Affibody(R) molecules in a cancer model
|
|
16 Mar 2007 |
Aida Pharmaceuticals Initiates Preclinical Research of Potential Anti-Cancer Treatment Vasostatin-Apo2L
|
|
16 Mar 2007 |
Neose Receives FDA Clearance to Commence U.S. Clinical Trials for NE-180
|
|
16 Mar 2007 |
Pacgen completes patient recruitment for Phase I/II trial of novel anti-fungal drug
|
|
15 Mar 2007 |
Lev Pharmaceuticals, Inc. Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
|
|
14 Mar 2007 |
Ambrilia and Mallinckrodt Announce IND Filing for Phase III Clinical Study of Improved Octreotide Formulation
|
|
14 Mar 2007 |
Maxygen Announces End of Co-Development Agreement
|
|
13 Mar 2007 |
Cangene Receives an Approvable Letter From the FDA for Human Growth Hormone
|
|
13 Mar 2007 |
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase IB/II Clinical Trial in Late Stage Cancer Patients
|
|
10 Mar 2007 |
Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
|
|
09 Mar 2007 |
Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies
|
